therapeutically effective amount of a population of isolated human mesenchymal stem cells. The present disclosure also concerns a method of treating sexual dysfunction in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of a population of isolated human mesenchymal stem cells as either a short-term or a long-term therapy, wherein said sexual dysfunction is a sexual disorder selected from the group consisting of hypoactive sexual desire disorder, orgasmic disorder, and sexual arousal disorder.

[0003a] In one aspect, the present disclosure refers to a use of a population of isolated human mesenchymal stem cells in the manufacture of a medicament for increasing libido and/or sexual satisfaction in a female patient, comprising that a therapeutically effective amount of the population of isolated human mesenchymal stem cells is to be administered to the female patient, wherein the human mesenchymal stem cells do not express STRO-1.

[0003b] In another aspect, the present disclosure refers to the use of a therapeutically effective amount of a population of isolated human mesenchymal stem cells as either a short-term or a long-term therapy in the manufacture of a medicament for treating sexual dysfunction in a female patient, comprising that a therapeutically effective amount of the population of isolated human mesenchymal stem cells is to be administered to the female patient, wherein said sexual dysfunction is a sexual disorder selected from the group consisting of hypoactive sexual desire disorder, orgasmic disorder, and sexual arousal disorder; and wherein the human mesenchymal stem cells do not express STRO-1.

[0004] In one example of the disclosure, the sexual dysfunction is hypoactive sexual desire disorder. In another example of the disclosure, the patient is a human. In yet another example of the disclosure, the patient is a female.

[0005] In one example of the disclosure, the mesenchymal stem cells are bone marrow-derived mesenchymal stem cells, cord blood-derived mesenchymal stem cells, adipose tissue-derived mesenchymal stem cells, or derived from induced pluripotent stem cells (iPSCs). In one example of the disclosure, the mesenchymal stem cells do not express STRO-1. In another example of the disclosure, the mesenchymal stem cells do not express CD45. In another example of the disclosure, the mesenchymal stem cells do not express fibroblast surface markers or have a fibroblast morphology. In another example of the disclosure, the mesenchymal stem cells are not genetically manipulated. In some examples of the disclosure, the mesenchymal stem cells are allogeneic stem cells. In other examples of the disclosure, the mesenchymal stem cells are autologous stem cells. In yet other examples of

CLAIMS

1. Use of a population of isolated human mesenchymal stem cells in the manufacture of a medicament for increasing libido and/or sexual satisfaction in a female patient, comprising that a therapeutically effective amount of the population of isolated human mesenchymal stem cells is to be administered to the female patient, wherein the human mesenchymal stem cells do not express STRO-1.

2. Use of a therapeutically effective amount of a population of isolated human mesenchymal stem cells as either a short-term or a long-term therapy in the manufacture of a medicament for treating sexual dysfunction in a female patient, comprising that a therapeutically effective amount of the population of isolated human mesenchymal stem cells is to be administered to the female patient, wherein said sexual dysfunction is a sexual disorder selected from the group consisting of hypoactive sexual desire disorder, orgasmic disorder, and sexual arousal disorder; and wherein the human mesenchymal stem cells do not express STRO-1.

3. The use of claim 2, wherein said sexual dysfunction is hypoactive sexual desire disorder.

4. The use of any one of claims 1-3, wherein the female patient is a human.

5. The use of any one of claims 1-4, wherein the mesenchymal stem cells are bone marrow-derived mesenchymal stem cells, cord blood-derived mesenchymal stem cells, adipose tissue-derived mesenchymal stem cells, or derived from induced pluripotent stem cells (iPSCs).

6. The use of any one of claims 1-5, wherein the mesenchymal stem cells are:

a) allogeneic stem cells; or

b) autologous stem cells.

7. The use of any one of claims 1-6, wherein the mesenchymal stem cells are to be coadministered with non-mesenchymal stem cells.

8. The use of any one of claims 1-7, wherein the mesenchymal stem cells:

a) do not express CD45; and/or

b) do not express fibroblast surface markers or have a fibroblast morphology; and/or

c) are not genetically manipulated.

9. The use of any one of claims 1-8, wherein the mesenchymal stem cells are to be administered:

a) in a single dose; or

b) in two or more doses.

10. The use of any one of claims 1- 9, ·wherein the mesenchymal stem cells are to be administered:

a) every 6 months; or

b) at least yearly.

11. The use of any one of claims 1-10, wherein the mesenchymal stem cells are to be administered systemically; optionally wherein the mesenchymal stem cells are to be administered by infusion or direct injection; optionally wherein the mesenchymal stem cells are to be administered by infusion or direct injection; optionally wherein the mesenchymal stem cells are to be administered intravenously, intraarterially, or

intraperitoneally.

12. The use of claim 11, wherein the mesenchymal stem cells are to be administered intravenously.

13. The use of any one of claims 1-12, wherein the mesenchymal stem cells are to be administered at a dose of:

a) about $20xl0^6$ mesenchymal stem cells; or

b) about $100x10^6$ mesenchymal stem cells.

14. The use of any one of claims 1-13, wherein the mesenchymal stem cells are to be obtained from a human donor and wherein a step of major histocompatibility complex (MHC) matching of the human donor to the female patient is not employed prior to the mesenchymal stem cells to be administered to the patient.

15. The use of any one claims 1-14, wherein treatment increases libido and/or sexual satisfaction or reduces sexual dysfunction in the female patient by at least 25%; optionally wherein the increase in libido and/or sexual satisfaction or reduction in sexual dysfunction is measured according to a Sexual Quality Of Life-Female questionnaire.